Adynovate 3000 Unit (Antihemophilic Factor (Recombinant), Pegylated KIT) 3000 UNIT

ADYNOVATE 3000 Unit is a recombinant antihemophilic factor used for bleeding prevention in hemophilia A. This pegylated kit offers extended protection, supporting clotting and reducing bleeding episodes.

Strength

3000 UNIT

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ADYNOVATE 3000 Unit is primarily used for on-demand treatment and routine prophylaxis in hemophilia A patients. It helps manage bleeding episodes and prevents them by replenishing clotting factor VIII. This medication is designed for intravenous administration, providing extended protection against bleeding.

Side Effects

ADYNOVATE 3000 Unit works by replacing the missing clotting factor VIII in individuals with hemophilia A. This helps to form blood clots and control bleeding. Common effects may include improved clotting ability and reduced frequency of bleeding episodes.

Precautions & Warnings

ADYNOVATE 3000 Unit should be handled with care, following proper storage and administration guidelines. It is essential to use this medication under medical supervision. Always check for any signs of allergic reactions or adverse effects during use.

Avoid Interactions

ADYNOVATE 3000 Unit may interact with certain medications or substances. It is important to discuss all current medications with a healthcare provider before starting this treatment. Avoid using this product if you have known allergies to its components.

Frequently Asked Questions

ADYNOVATE 3000 Unit is used for the treatment and prevention of bleeding episodes in individuals with hemophilia A.

ADYNOVATE 3000 Unit is administered intravenously, typically under medical supervision.

Common effects include improved clotting ability and reduced frequency of bleeding episodes.

Yes, ADYNOVATE 3000 Unit is designed for routine prophylaxis to prevent bleeding episodes in hemophilia A patients.

It is important to follow proper storage and administration guidelines and to use this medication under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.